Lineage Cell Therapeutics (LCTX)
(Delayed Data from AMEX)
$0.93 USD
+0.08 (9.53%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $0.92 -0.01 (-0.54%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LCTX 0.93 +0.08(9.53%)
Will LCTX be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for LCTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LCTX
NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains?
What Makes Lineage Cell (LCTX) a New Buy Stock
LCTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lineage Cell (LCTX) Reports Q2 Loss, Tops Revenue Estimates
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates
Other News for LCTX
Lineage Cell Therapeutics Inc (LCTX) Q2 2024 Earnings Call Highlights: Strategic Alliances and ...
OpRegen? (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium
Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance?, at the 59th Annual Inner Ear Biology Workshop
Buy Rating Affirmed for Lineage Cell Therapeutics Amid Strategic Partnerships and Pipeline Progress
Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference